Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PST-611 in Geographic Atrophy Secondary to AMD
NCT07705568Phase 2Not yet recruiting
- Sponsor
- Eyevensys
- Start
- Sep 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 2 trial of EYS611 in geographic atrophy (GA), age-related macular degeneration (AMD), sponsored by Eyevensys. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
EYS611
03
Conditions
geographic atrophy (GA)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT07705568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07705568.